WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413378
CAS#: 1401998-36-4 (mesylate)
Description: CUDC-907 mesylate is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.
Hodoodo Cat#: H413378
Name: CUDC-907 mesylate
CAS#: 1401998-36-4 (mesylate)
Chemical Formula: C24H28N8O7S2
Exact Mass: 0.00
Molecular Weight: 604.660
Elemental Analysis: C, 47.67; H, 4.67; N, 18.53; O, 18.52; S, 10.60
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1401998-36-4 (mesylate) 1339928-25-4 (free base)
Synonym: CUDC907 mesylate; CUDC 907 mesylate; CUDC-907 mesylate; CUDC907; CUDC 907; CUDC-907; fimepinostat;
IUPAC/Chemical Name: 5-Pyrimidinecarboxamide, N-hydroxy-2-(((2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl)thieno(3,2-d)pyrimidin-6-yl)methyl)methylamino)-, methanesulfonate (1:1)
InChi Key: CFLAKAHRZMPILU-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H24N8O4S.CH4O3S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14;1-5(2,3)4/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32);1H3,(H,2,3,4)
SMILES Code: O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO.CS(=O)(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Soluble in DMSO | 0.0 | 100.00 |
The following data is based on the product molecular weight 604.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Okabe S, Tanaka Y, Moriyama M, Gotoh A. Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome- positive leukemia cells. Cancer Chemother Pharmacol. 2020 Feb;85(2):401-412. doi: 10.1007/s00280-019-04022-x. Epub 2020 Jan 4. PMID: 31901955.
